Introduction {#Sec1}
============

Called as "the Great Imposter," systemic lupus erythematosus (SLE) is a chronic and complex autoimmune disease with multisystem manifestations \[[@CR1], [@CR2]\]. The disease prevalence is estimated about 5 million people worldwide, and it occurs mostly before the age of 45 years \[[@CR3]--[@CR5]\]. The loss of central and peripheral tolerance to self, as a result of genetic susceptibility or environmental factors, is proposed to be a crucial first step in the SLE development \[[@CR6], [@CR7]\].

Certain lines of evidence suggested that a break in central B cell tolerance results in autoreactive clones to reach the periphery \[[@CR8]\], which followed by autoantibodies' production and immune complex deposition and finally damage the end organ \[[@CR9], [@CR10]\]. Likewise, an aberrant TCR signaling followed by hyper-responsiveness of T cells has been shown in SLE patients \[[@CR11]\]. The genome-wide association studies (GWAS) coupled with gene expression profiling data shed light on the critical role of genes involved in B cell receptor (BCR) and T cell receptor (TCR) signaling pathways in SLE pathogenesis \[[@CR7]\]. Despite numerous strong-minded studies have been done, the SLE pathogenesis is still far from clear. Many studies used bioinformatics approach such as enrichment analysis and determined pathways implicated in multifactorial disease pathogenesis. To the best of our knowledge, there is no study with deep insight into the implicated pathways in SLE.

Towards a better intuition of molecular mechanisms involved in multifactorial immune-related diseases especially SLE, lots of researchers acknowledge the gene network approach which helps to prioritize main driver genes and pathways, to propose a better drug development \[[@CR12]\]. Bayesian networks (BNs), as a worthwhile powerful gene network construction methods, integrate and model biological data with causal relationships \[[@CR13]--[@CR17]\]. By applying gene expression data of SLE patients, Li et al. recently reconstructed a BN, in which prior edges were randomly sampled based on the text-mining in SLE pathogenesis \[[@CR12]\]. Remarkably, some methods such as BNrich were also developed based on BN properties \[[@CR18]\] which identifies significant genes (nodes) and biological relationships (edges). The BNrich method has two key concepts: (1) the structure of BN is reconstructed by the signaling pathway structure, and (2) the expression level of the gene (node) is modeled as a regression function of expression levels of its upstream genes (parents) \[[@CR18]\].

As a method that is widely used to integrate gene expression data, *cross-platform normalization* (CPN) (1) increases sample sizes and improves gene signature selection \[[@CR19]--[@CR23]\], (2) rises the heterogeneity of the overall estimate, and (3) decreases the effects of individual study-specific biases \[[@CR22], [@CR23]\]. On the other hand, the mixture model, known as a model averaging method, is well documented to integrate node and edge parameters based on their distribution \[[@CR24]\].

With systems biology approach, we aimed to illustrate the superiority of using CPN and mixture model method and the BNrich to better understand new aspects of underlying molecular mechanisms in the pathogenesis of complex diseases such as SLE. Here, we concentrated on SLE, BCR, and TCR signaling pathways, which are among the most enriched pathways in SLE, to highlight significant alterations of those pathways in SLE patients compared to healthy controls. Besides the altered gene expression level, we demonstrated several significant intergenic relationships which can be proposed as effective targets for therapeutic intervention in SLE patients.

Methods {#Sec2}
=======

The human peripheral blood mononuclear cell (PBMC) microarray datasets (*n* = 6) associated with SLE were downloaded and integrated by CPN method. Subsequently, we employed SLE, TCR, and BCR signaling pathways as structures of BNs and we determined significant node and edge parameters by BNrich method in each dataset independently. Consequently, significant parameters of all datasets were merged through mixture model method and key driver parameters in the selected pathways were defined (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Workflow and analysis procedure to identify signaling pathway alterations in SLE patients. At the first step, human peripheral blood mononuclear cell (PBMC) microarray datasets associated with SLE, which were generated using three platforms, were downloaded and each paired data related to the same platform integrated by CPN method. Subsequently, SLE, TCR, and BCR signaling pathways were employed as structures of BNs and trained by three major datasets independently by BNrich method. Afterwards, the differences between any paired corresponding parameters related to patients and controls were examined by independent *t* test. Consequently, the significant parameters merged by the mixture model to achieve the key driver parameters in studied pathways

Gene expression datasets {#Sec3}
------------------------

The human PBMC microarray datasets that contain both SLE patient and healthy control (HCs) samples, published or updated in 2010--2019, were downloaded from the Gene Expression Omnibus (GEO) database: GSE 17755 \[[@CR25]\], GSE 12374 \[[@CR26]\], GSE 50772 \[[@CR27]\], GSE 81622 \[[@CR28]\], GSE 121239 \[[@CR29]--[@CR31]\], and GSE 126307 \[[@CR32]\]. We described the details of the data in Table [1](#Tab1){ref-type="table"}. Table 1Description of the datasets used in the studyNo.GSE no.GPL/platformNo. of sampleCell typeUpdate (year)RaceSLE patientsControls1177551291/Hitachisoft2255PBMC2010Japanese2123741291/Hitachisoft116PBMC2012Japanese350772570/Affymetrix6120PBMC2015Unknown^a^48162210558/Illumina3025PBMC2016Unknown^b^512123913158/Affymetrix65^c^20PBMC2018Caucasian/African American^d^612630713369/Illumina319PBMC2019Several races^ea^The data were collected in the USA/South San Francisco, but the race of subjects is unknown^b^The data were collected in the USA/Dallas, but the race of subjects is unknown^c^Only the data related to the first visit (v1) samples of any patient were entered in the analysis^d^This subset of the samples is derived from a preliminary dataset which were collected in the USA/Johns Hopkins University School of Medicine Institutional, and most of the race of subjects (92.8%) are Caucasian and African American^e^The data collected in USA/Dallas, but the race of subjects is Australian, Australian (Irish/Scottish descent), born in India---ethnicity unknown, Caucasian, Caucasian/Japanese, English, Filipino, Indian, Iraqi, Latin American, Persian, Spanish, and White Australian/Anglo-Celtic

Cross-platform normalization {#Sec4}
----------------------------

Each expression dataset was preprocessed and normalized by *normalizeQuantiles* function from R package *limma* \[[@CR33]\]. Then, we performed CPN \[[@CR23]\] with *Reduce* function in R to integrate each paired gene expression data emanated from the same platform. Finally, we have three major datasets from Affymetrix, Illumina, and Hitachisoft; each platform has a SLE patient group and a HC group. Afterwards, the empirical Bayes method (ComBat) from the R package *sva* was used for batch effect removal \[[@CR34]\].

BNrich approach {#Sec5}
---------------

To reconstruct BN structures, the SLE (hsa:05322), TCR (hsa:04660), and BCR (hsa:04662) signaling pathways were implemented. All of the pathways were extracted directly from the KEGG database (Release 90.0, April 1, 2019) \[[@CR35]\].

In the parameter estimate step, the mean value of the expression for each gene (node) can be modeled as a linear regression of its parents' (upstream) gene expression \[[@CR18]\]. When *Y* gene has *X*~1~, *X*~2~...*X*~*p* − 1~ parents in the network, and $\documentclass[12pt]{minimal}
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In the SLE- and HC-associated trained BNs, the constant coefficient *β*~(s/h)0~ demonstrates the expression level of *Y* gene, known as a node parameter. The coefficients of *X*~1~, *X*~2~...*X*~*p* − 1~ are the parameters of the edge in the trained BNs which reveal a biological relationship between two genes, *Y* and *X*. For example, the value of *β*~*s*3~ is the edge parameter between *Y* and *X*~3~ genes in the network structure related to SLE patient data and shows the value of the biological relationship between these two genes. The *ε*~*c*~ and *ε*~*h*~ are the residual values.

Using Eq. [1](#Equ1){ref-type=""}, the node and edge parameters of the BN structures (derived from SLE, BCR, and TCR signaling pathways) were estimated for SLE patient- and HC-gene expression datasets of the three related platforms, separately. Subsequently, we compared the parameters of trained networks in SLE patients (*β*~*s*~) with HCs (*β*~*h*~) by independent *t* test \[[@CR36]\] and gained the *β*^∗(*j*)^ (*j* ∈ {*A*, *I*, *H*}) which is the significant parameter based on false discovery rate (*FDR*~*j*~ \< 0.05) for Affymetrix (A), Illumina (I), and Hitachisoft (H) datasets.
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Accordingly, the significant parameters had been distributed as follows: $$\documentclass[12pt]{minimal}
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Therefore, we had up to three significant parameters for each node (or edge) which are *β*^∗(*A*)^, *β*^∗(*I*)^, and *β*^∗(*H*)^.

Merge significant parameters via mixture model {#Sec6}
----------------------------------------------

By using the mixture model approach \[[@CR38]\], we merged the significant parameters of three platform-associated datasets and calculated the significant final parameters, both at the node and edge level. The final parameters, *β*~*f*~, have a normal distribution, and their mean and variance were defined by: $$\documentclass[12pt]{minimal}
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where *N*~*A*~ = 166, *N*~*I*~ = 95, and *N*~*H*~ = 94 were the number of subjects in Affymetrix, Illumina, and Hitachisoft. Since the range of the variances across final parameters is varied, their mean is divided by the standard deviation to achieve comparable parameters. Hence, we plotted the figures based on the following definition: $$\documentclass[12pt]{minimal}
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If the parameter *β*^∗(j)^ in each dataset was not significant, its mean and variance were considered to be zero in calculating the corresponding final parameter. When the *β*~*f*~ was associated with the node parameters, the sign of *μ*^∗^(*β*~*f*~) indicated upregulation (+) or downregulation (−) of the gene and the absolute value of *μ*^∗^(*β*~*f*~) was used to measure the value of activation or inhibition. Where the *β*~*f*~ was associated with the edge parameters, the sign of *μ*^∗^(*β*~*f*~) indicated increasing (+) or decreasing (−) biological function and the absolute value of *μ*^∗^(*β*~*f*~) was used to measure the value of these increased or decreased functions.

Results {#Sec7}
=======

Data integration using CPN {#Sec8}
--------------------------

After downloading the six mentioned datasets (Table [1](#Tab1){ref-type="table"}), to reduce the batch effect generated between different arrays, each paired data emanated from the same platform was integrated using the ComBat algorithm. The efficiency of the ComBat process in our integration for batch removal can be verified by the comparative boxplots and principle component analysis (PCA) plots (Fig. [2](#Fig2){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}). Fig. 2Graphical demonstration of the batch effect removal using ComBat for Affymetrix platforms. Boxplot (**a**) and PCA plot (**b**) show the gene expression distributions and the samples of microarray datasets before batch effects removal respectively. As the same way, Boxplot (**c**) and PCA plot (**b**) show the corresponding concepts after batch removal. The boxplots distributions show the normalization and decreasing technical diversities between datasets; and in the horizontal axis, the j^th^ healthy control subjects and the j^th^ SLE patient in the i^th^ dataset were illustrated with DiH.j and DiS.j, correspondingly. In the PCA plots, each dot represents one sample, and the color indicates its dataset

We did not observe any genes lost after performing CPN on Illumina and Hitachisoft related data, while in the Affymetrix platform, information of about 5.4% and 8.5% of genes in the datasets GSE 50772 and GSE 121239 were lost correspondingly. Considering the CPN benefits, we pursue of using all 166 samples of Affymetrix platform simultaneously instead of analyzing 81 or 85 individual samples (Table [2](#Tab2){ref-type="table"}). Table 2The percentage of lost genes after running CPNGSE no.PlatformGenes (***n***)Genes after CPN (***n***)Lost genes (%)50772Affymetrix19,68918,6275.412123920,3518.581622Illumina30,50030,500012630730,500017755Hitachisoft13,10213,10201237413,1020

Identify significant parameters using BNrich {#Sec9}
--------------------------------------------

To identify significant parameters, including nodes and edges, in SLE patients against HCs in every major dataset, the SLE, TCR, and BCR signaling pathways were utilized as structures of BN and significant parameters (nodes and edges) were determined using BNrich method. Table [3](#Tab3){ref-type="table"} presents the number of significant node and edge parameters in the three dataset-associated platforms based on FDR \< 0.05 for SLE, TCR, and BCR signaling pathways. Table 3The number of all significant node and edge parameters of BNs extracted from SLE, TCR, and BCR signaling pathways obtained via BNrichSignaling pathwaysFDR \< 0.05AffymetrixIlluminaHitachisoftNodesEdgesNodesEdgesNodesEdges**SLE**73410811507**TCR**82161811207575**BCR**5710368915660

According to our results, 34 significant nodes and the C1QB → C2 edge were common among all datasets in the SLE pathway. Across datasets of all platforms, 53 nodes and 26 edges of the TCR signaling pathway and 36 nodes and 30 edges of the BCR signaling pathway were common. All significant parameters of different platforms, based on three examined signaling pathways, are presented in Additional file [2](#MOESM2){ref-type="media"}.

Determine the key driver parameters of signaling pathways via mixture model {#Sec10}
---------------------------------------------------------------------------

To distinguish the altered signaling pathway parameters in SLE patients compared to HCs, the identified significant parameters of all dataset merged by the mixture model method (Eqs. [4](#Equ4){ref-type=""} and [5](#Equ5){ref-type=""}), the range of *μ*^∗^(*β*~*f*~) in all nodes and edges are represented in Table [4](#Tab4){ref-type="table"}. Table 4The minimum and maximum final parameter values of nodes and edges in three signaling pathwaysSLETCRBCRNodesEdgesNodesEdgesNodesEdges*μ*^∗^(*β*~*f*~)**Min**− 1.70− 0.46− 1.68− 1.01− 1.39− 0.96**Max**2.370.551.431.121.430.94

The three nodes and edges that have the extreme values of *μ*^∗^(*β*~*f*~) in each desired pathway are illustrated in Table [5](#Tab5){ref-type="table"}, and the all *μ*^∗^(*β*~*f*~) represented in Additional file [2](#MOESM2){ref-type="media"}. Table 5The top three nodes and edges of the studied pathwaysNodesEdgesDownUpIncreasing biological functionDecreasing biological function**SLE**SNRPD3FCGR1AC1R → C4AC1QA → C2HLA-DPB1CTSGC1QB → C4ACD86 → CD28HLA-DMAELANEC4B → C3C1S → C4A**TCR**CD3EBCL10RASGRP1 → NRASNCK2 → PAK3PPP3CCPAK5CBLB→FYNMAP2K1 → MAPK1CBLBMAPK14PPP3CB → NFATC3CD3E → FYN**BCR**INPP5DBCL10AKT3 → IKBKGSYK → PIK3AP1PPP3CCPIK3AP1MAPK1 → FOSMAP2K1 → MAPK1CD81IFITM1PPP3CC → NFATC1VAV1 → RAC2

Among genes involved in the clearance mechanism of SLE pathway, *TRIM21*, *H2AX*, *C1QA*, *C1QB*, *H2BC12*, and *H2BC12* were mostly upregulated. However, *SNRPD3*, *SSB*, *MACROH2A2*, *GRIN2B*, and *C4B* were mostly downregulated. In antigen presentation process mediated by MHCII, nodes such as *HLA*-*DPB1*, *HLA*-*DMA*, *CD80*, *IL10*, and *TNF* and three edges, *CD80* and *CD86* to *CD28* and *DD40LG* to *CD40*, were found to be dysregulated.

In addition, our analysis showed that among genes which participated into damaging of the end organ, the expression of genes like *FCGR1A*, *CTSG*, *ELANE*, *FCGR3B*, *FCGR3B*, and *C1QA* were increased and the expression of *C7*, *C3*, *C4B*, *C2*, and *C4A* genes were decreased. Particularly, in that functional part of SLE pathway, we also found dysregulation of several important edges like *C1R*, *C1S*, and *C1QB* to *C2* (Fig. [3](#Fig3){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}). Fig. 3The alterations in SLE signaling pathway based on calculated final parameters. The representation design of KEGG-extracted SLE signaling pathways (**a**), genes involved in autoantigen clearance (**b**), antigen presentation mediated by MHCII (**c**), and tissue injury and end-organ damage (**d**). The color and size of nodes reflect the values and the absolute values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the upregulation or downregulation of genes. Moreover, the color of the edges reflects the values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the increasing or decreasing biological function

By integrating BCR and TCR signaling pathway information with gene expression data, we identified many of the altered key driver genes in these pathways among SLE patients. Our results revealed 46 shared dysregulated nodes (e.g., *AKT1*, *AKT2*, *AKT3*, *MALT1*, *MAPK3*, SOS) and 64 common dysregulated edges (e.g., *PIK3CA* to *AKT1* and *AKT2*, *IKBKB* to *NFKBIA*, *NFKBIB* and *NFKBIE*) between these two pathways (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}). Fig. 4The alterations in TCR signaling pathway. The schematic figure of the TCR signaling pathway in KEGG (**a**), and the TCR signaling pathway alterations based on calculated final criteria (**b**). The color and size of nodes reflect the values and the absolute values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the upregulation or downregulation of genes. Moreover, the color of the edges reflects the values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the increasing or decreasing biological functionFig. 5The alterations in the BCR signaling pathway. The schematic figure of the BCR signaling pathway in KEGG (**a**), and the BCR signaling pathway alterations based on calculated final criteria (**b**). The color and size of nodes reflect the values and the absolute values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the upregulation or downregulation of genes. Moreover, the color of the edges reflects the values of the *μ*^∗^(*β*~*f*~), respectively, and it is equivalent to the increasing or decreasing biological function

Discussion {#Sec11}
==========

In the context of identifying SLE gene signature, previous studies have been limited to gene expression level regardless of intergenic relationship. In the present study, for the first time, through data aggregation via BNrich, CPN, and mixture model method, we merged several diverse gene expression data into SLE, TCR ,and BCR signaling pathways and unraveled key genes and intergenic relationships that may serve as effective targets for therapeutic intervention in SLE patients. By using the CPN method, we increased the sample size and decreased the heterogeneity of the samples in comparison to previous studies \[[@CR25]--[@CR32]\]. According to BNrich properties, we could integrate two levels of biological data, gene expression and signaling pathways. Hence, the value of the node and edge parameters in addition to being influenced by gene expression data also depends on the topology of the underlying pathway \[[@CR18]\]. For instance, in the Illumina platform, the mean value of the final parameter in *PIK3CB* gene was 1.7 and − 0.5, and the mean value of the final parameter in edge PPP3CC → NFATC3 was − 0.07 and 0.12, in TCR and BCR signaling pathways, correspondingly (Additional file [2](#MOESM2){ref-type="media"}). Moreover, we used the mixture model, as a model averaging method, to determine the key driver parameters across all datasets. In contrast to model selection, the mixture model dramatically minimizes the risk relative to selection \[[@CR24]\].

First, we investigated SLE signaling pathway (hsa:05322), which included three sections: (1) autoantigen clearance mechanism, (2) antigen presentation mediated by MHCII, and (3) tissue injury and end-organ damage. The uncleaned apoptotic components which recognized by both the innate and the adaptive immune systems can trigger the pathogenesis of SLE. Therefore, the dysregulation of effective genes involved in the clearance of apoptotic components has a fundamental role in SLE \[[@CR39]--[@CR43]\]. In the same vein, we showed significant upregulation of 69 genes which include *TRIM21*, *C1Q* gene family, and *SNRPD1* and significant downregulation of 15 genes which include *SNRDP3*, *SSB*, and *GRIN2B* (Fig. [3](#Fig3){ref-type="fig"}b). Over the recent years , *TRIM21*, *SSB*, and *C1Q* have gained particular attention in SLE \[[@CR44]--[@CR46]\]. In line with earlier studies, we also underscored the dysregulation of histone gene family (H2A, H2B, H3, and H4) \[[@CR47]\]. The clearance procedure followed by antigen presentation was mediated by MHCII. While *CD80*, *CD86*, *IL10*, and *TNF-α* as key mediators of this pathway were distinctively activated, the HLA gene family members (*DPB1*, *DQA1*, *DMA*, etc.) showed the significant reduction (Fig. [3](#Fig3){ref-type="fig"}c). The association of HLA genes with childhood- and adult-onset SLE was represented recently \[[@CR48]\]. Besides, the elevated level of serum *TNF-α* has been shown in SLE patients. Using anti-TNF monoclonal antibodies like infliximab and etanercept to treat SLE patients further confirmed the importance of TNF as a targeting agent \[[@CR49]\]. Despite the negative results for *CD40LG* and *CD40* node parameters, the edge parameter between them showed a positive biological function. Therefore, we further highlight the therapeutic effect of *CD40-CD40LG* pathway blockade in SLE \[[@CR50]\]. Although *CD28* expression was reduced, *CD80* → *CD28* biological function was enhanced significantly (Fig. [3](#Fig3){ref-type="fig"}c). At the end of the SLE signaling pathway, end-organ damage occurs via dysregulation of several genes. Among them, the deficiencies of early complement proteins, including *C1*, *C4*, and *C2*, were strongly associated with the development of SLE \[[@CR51]\]. Our results showed that not only the parameters of *C3*, *C7*, and *C4B* were reduced but also *C1R* → *C2*, *C1QA* → *C2*, and *C1S* → *C4A* biological functions were lessened (Fig. [3](#Fig3){ref-type="fig"}d). Additionally, our findings showed augmented *ELANE*, *FCGR1A*, *FCGR2A*, *FCGR3B*, and *CTSG* node parameters. By applying a multicohort analysis of 7471 transcriptomic profiles, Haynes et al. have just introduced *ELANE* as an "Under-appreciated SLE MetaSignature." \[[@CR52]\] In a recent study, the *FCGR2A* polymorphisms have been linked to SLE susceptibility in Mexican patients \[[@CR46]\].

As outlined earlier, the fundamental importance of BCR and TCR signaling pathways in SLE pathogenesis has been well established via both clinical and experimental evidence \[[@CR53]--[@CR55]\]. In the TCR signaling pathway, we observed lower expression of several genes like *CBLB*, *PPP3CC*, *NFKB1*, *CD3E*, and *ZAP70*. Recently, a study by Matsuo et al. revealed that a genetic mutation in *ZAP70* resulted in the TCR signaling defect which followed by T follicular helper (Tfh) cell development and the manifestation of lupus-like systemic autoimmunity \[[@CR56]\]. Having several significant edges with the other nodes proposes *ZAP70* as a hub gene of the TCR signaling pathway implicated in SLE pathogenesis. Interestingly, the perturbation in TCR culminated to enhanced expression of *CDK4*, *IL2*, and *IL10* genes. In the BCR signaling pathway, the most up- and downregulated genes were *BCL10* and *INPP5D*, respectively. Furthermore, we also identified significant lower expression of *CD79A* and *CD79B* (also known as Igα and Igβ, respectively). In a meta-analysis of GWAS results, Julià et al. reported BCR signaling pathway as the most significant biological process and *BCL10* and *CD79A* among top single markers associated with SLE \[[@CR57]\].

Interestingly, our results addressed the dysregulation of several noteworthy node and edge parameters shared by both TCR and BCR signaling pathways. Among them *PI3K*/*AKT* signaling pathway and *VAV* gene homologs were altered; *AKT1*, *AKT2* and *VAV1*, *VAV2* expression levels were particularly reduced (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). Previously, some researcher confirmed these results and proved phosphorylation level of *AKT* in SLE patients, which further support the major role of PI3K/Akt/TSC/mTOR signaling pathway in the disease \[[@CR58], [@CR59]\]. According to our results, the MAPK signaling pathway as an effective subnetwork of TCR and BCR signaling in SLE pathogenesis \[[@CR59]\] also displayed a significant dysregulation, especially higher expression of *MAPK1*, *MAPK3*, and *PPP3CA* genes. Similarly, the strong association of *PPP3CA* with SLE-like disease has been described as new \[[@CR60]\]. Moreover, we observed the reduced expression of JUN and FOS together with some increased or decreased biological relations with their neighbors in both TCR and BCR pathways. JUN and FOS are subunits of the transcription factor AP-1 which regulates cytokines and chemokines of TCR and BCR pathways in inflammatory and autoimmune disease \[[@CR61]\].

Further investigation will be required to evaluate the efficiency of *CD80* and *CD86* → *CD28*, *C1R* and *C1QA* → *C2*, and *C1S* → *C4B* biological functions, PI3K/AKT signaling pathways, besides *JUN* gene as therapeutic targets in SLE disease. Moreover, analyzing the RNA-seq datasets could be better for distinguishing expression levels and biological relationships of genes' isoforms in considered signaling pathways. It is necessary to examine the BNrich among some other autoimmune diseases in order to identify SLE signature genes more precisely.

Conclusions {#Sec12}
===========

In the present study, we exploited BNrich to hybridize intergenic relations inferred from signaling pathways and gene expression profiling to improve the insight about SLE as a complex disease. We figured out the significant genes and intergenic relationships and systemic alterations in SLE, TCR, and BCR signaling pathways. Through cross-platform normalization and meta-analysis, large-enough SLE patients were analyzed. Since multiple platforms were utilized, the effects of individual study-specific biases were reduced.

Notably, the proposed computational methodology can be applied to a variety of complex diseases to illuminate new mechanistic insights in their pathogenesis.
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**Additional file 1.** Batch effect removal results. The box plots and PCA plots related to CPN results for Hitachisoft and Illumina platforms. **Additional file 2.** Significant and final parameters. The significant parameters of different platforms and the final parameters based on the mixture model in three examined signaling pathways.
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